Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Losartan
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Arbor Pharmaceuticals

    • Most Recent Events

    • 10 Feb 2021 Number of treatment arms has been increased from 4 to 8, thus adding 4 new arms for withdrawal phase (2 arms for active comparator and 2 arms for placebo). The existing 4 arms have also been labelled as double-blind phase arms and open-label phase arms.
    • 10 Feb 2021 Status changed from active, no longer recruiting to completed.
    • 13 Jul 2020 Planned End Date changed from 1 Apr 2020 to 27 Sep 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top